Description: Vallon Pharmaceuticals, Inc. engages in developing and manufacturing medicines for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy disorder. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Home Page: www.vallon-pharma.com
VLON Technical Analysis
Two Logan Square
Philadelphia,
PA
19103
United States
Phone:
267 607 8255
Officers
| Name | Title |
|---|---|
| Mr. David C. Baker | CEO, Pres & Director |
| Ms. Leanne M. Kelly | Chief Financial Officer |
| Dr. Ofir Levi Ph.D. | Consulting |
| Dr. Timothy M. Whitaker | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8381 |
| Price-to-Sales TTM: | 247.2775 |
| IPO Date: | 2021-02-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |